Foghorn Therapeutics (FHTX) Capital Expenditures (2019 - 2025)
Foghorn Therapeutics' (FHTX) quarterly Capital Expenditures came in at -$28000.0 in Q2 2025, down 264.71% year-on-year from $17000.0 in Q2 2024, and down 200.0% quarter-over-quarter from $28000.0 in Q1 2025.
Foghorn Therapeutics (FHTX) Capital Expenditures (2019 - 2025) Analysis & Trends
Foghorn Therapeutics' Capital Expenditures history runs 7 years deep, the most recent figure standing at -$28000.0 for Q2 2025.
- On a quarterly basis, Capital Expenditures fell 264.71% year-over-year to -$28000.0 in Q2 2025; TTM through Mar 2026 was -$28000.0, a 103.36% decrease from a year earlier, with the FY2024 full-year figure at $906000.0, down 25.98% from the prior year.
- Capital Expenditures eased to -$28000.0 in Q2 2025 per FHTX's latest filing, from $28000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $2.0 million in Q2 2021 and bottomed at -$2.9 million in Q4 2021.
- The 5-year median for Capital Expenditures is $165500.0 (2021), against an average of $143611.1.
- Across the five-year window, Capital Expenditures slumped 276.96% in 2022 and surged 2750.0% in 2023, its largest moves.
- Year by year, Capital Expenditures stood at -$2.9 million in 2021, then surged by 98.5% to -$44000.0 in 2022, then jumped by 2750.0% to $1.2 million in 2023, then plunged by 58.92% to $479000.0 in 2024, then sank by 105.85% to -$28000.0 in 2025.
- Per Business Quant, the three latest FHTX Capital Expenditures figures stand at -$28000.0 (Q2 2025), $28000.0 (Q1 2025), and $479000.0 (Q4 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Foghorn Therapeutics | 352.57 Mn | 263.66 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -28,000.00 |
| Jun 30, 2025 | -28,000.00 |
| Mar 31, 2025 | 28,000.00 |
| Mar 31, 2025 | 28,000.00 |
| Dec 31, 2024 | 479,000.00 |
| Dec 31, 2024 | 479,000.00 |
| Sep 30, 2024 | 309,000.00 |
| Sep 30, 2024 | 309,000.00 |
| Jun 30, 2024 | 17,000.00 |
| Jun 30, 2024 | 17,000.00 |
| Mar 31, 2024 | 101,000.00 |
| Mar 31, 2024 | 101,000.00 |
| Dec 31, 2023 | 1.17 Mn |
| Dec 31, 2023 | 1.17 Mn |
| Sep 30, 2023 | -29,000.00 |
| Sep 30, 2023 | -29,000.00 |
| Jun 30, 2023 | -211,000.00 |
| Jun 30, 2023 | -211,000.00 |
| Mar 31, 2023 | 298,000.00 |
| Mar 31, 2023 | 298,000.00 |